SEC Form 4 · accession 0000950138-17-000754
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
J Martin Carroll
Director
Period of report
Nov 9, 2017
Accepted (ET)
Nov 13, 2017 · 4:17 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Nov 9, 2017 | P | 5,000 | $20.4187 | A | 23,423 | D | |
| Ordinary Shares | holding | — | — | — | 131 | I | By Grantor Retained AnnuityTrust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price represents a weighted average. The shares were purchased in multiple transactions at prices ranging from $20.39 to $20.46, inclusive. Mr. Carroll will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares purchased at each price within the range.
Remarks
This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.